Rosiglitazone Maleate/Metformin Hydrochloride

马来酸罗格列酮/盐酸二甲双胍

Report date: 2026/03/13 20:02:36

Base Information

Drug NameRosiglitazone Maleate/Metformin Hydrochloride
Drug Alias NameRosiglitazone/Metformin罗格列酮/二甲双胍Rosiglitazone Maleate•Metformin Hydrochloride马来酸罗格列酮和盐酸二甲双胍马来酸罗格列酮•盐酸二甲双胍 +[11] 
ClassificationSmall molecules
Mechanisms of ActionPeroxisome proliferator-activated receptor γ agonistsProtein kinase AMP-activated non-catalytic subunit beta 1 activators
TargetsProtein kinase AMP-activated non-catalytic subunit beta 1Peroxisome proliferator-activated receptor γ
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryUnited States
Original Approved Date2002/10/10
Country/TerritoryUnited StatesMainland China
CombinationsYes Metformin HydrochlorideRosiglitazone Maleate
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline Australia Pty Ltd
Inactive CompaniesSb Pharmco Puerto Rico Inc
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeA10BD03
Related LinksKEGG